Valerio Therapeutics SA 2016 IR
The report highlights Onxeo's progress in 2016, focusing on its clinical-stage biotechnology developments in orphan oncology, including its flagship programs Livatag, Beleodaq, and AsiDNA. During the year, the company completed the acquisition of DNA Therapeutics, expanding its pipeline with signal-interfering DNA technology. Onxeo also established a US subsidiary in New York and raised €12.5 million to fund its ongoing research and development. In terms of sustainability, the company reported on its social and environmental responsibility, highlighting its highly feminized workforce with 70% women and its commitment to occupational health and safety.
Company: Valerio Therapeutics SA
Sector: Professional & technical services
Country: France
Year: 2016
Type: IR
Pages: 191
Back to company
Valerio Therapeutics SA
Registration Document
The report highlights Onxeo's progress in 2016, focusing on its clinical-stage biotechnology developments in orphan oncology, including its flagship programs Livatag, Beleodaq, and AsiDNA. During the year, the company completed the acquisition of DNA Therapeutics, expanding its pipeline with signal-interfering DNA technology. Onxeo also established a US subsidiary in New York and raised €12.5 million to fund its ongoing research and development. In terms of sustainability, the company reported on its social and environmental responsibility, highlighting its highly feminized workforce with 70% women and its commitment to occupational health and safety.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Published
Apr 24, 2017
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees